

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 451 750 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
27.11.1996 Bulletin 1996/48

(51) Int. Cl.⁶: **A61K 31/22, A61K 31/19**

(21) Application number: **91105502.8**

(22) Date of filing: **08.04.1991**

(54) **Use of short chain fatty acid containing lipids to maintain gastrointestinal integrity and function in patients**

Verwendung von kurzkettigen Fettsäuren enthaltenden Lipiden zur Aufrechterhaltung der Integrität und der Funktion des Magen-Darm-Kanals

Utilisation de lipides contenant des acides gras à courte chaîne, pour maintenir l'intégrité et le fonctionnement gastro-intestinal chez des patients

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

(30) Priority: **10.04.1990 US 506938**

(43) Date of publication of application:
16.10.1991 Bulletin 1991/42

(73) Proprietor: **CLINTEC NUTRITION COMPANY**
Deerfield, Illinois 60015 (US)

(72) Inventors:

- Cotter, Richard
Grand Rapids, Mich. 49506 (US)
- Tucker, Hugh
Barrington, Ill. 60010 (US)

(74) Representative: **Vuille, Roman et al**
Avenue Nestlé 55
1800 Vevey (CH)

(56) References cited:
WO-A-90/12080
US-A- 4 721 716

US-A- 4 585 764

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 451 750 B1

Description

The present invention relates to the use of short chain fatty acids containing lipids in clinical nutrition, specifically for the preparation of a medicament for maintaining gastrointestinal integrity and function in patients.

Lipids containing fatty acids having 2 to 6 carbon atoms, (short chain fatty acids - SCFA), are known to be produced in the gastrointestinal tract, in particular in the colon. Short chain fatty acids include acetic, propionic, butyric, isobutyric, pentanoic, isopentenoic and caproic. Typically, the short chain fatty acids are produced by bacterial fermentation. The substrates for the production of short chain fatty acids by bacterial fermentation are carbohydrates that are generally fibrous in nature.

The short chain fatty acids are used by the gastrointestinal mucosa as an energy substrate to maintain integrity and function. One method of providing gastrointestinal mucosa with short chain fatty acids is to utilise a dietary fiber which is converted by luminal microorganism digestion to fatty acids. Due to a variety of clinical reasons, the ability of the gastrointestinal mucosa to use short chain fatty acids as an energy source can be impaired.

When in the course of human disease, or therapy for disease, the bacterial flora of the gut is modified, reduced, or eliminated, its ability to provide short chain fatty acids as an energy substrate is impaired. There are a number of procedures, specifically with respect to hospitalised individuals that can greatly alter or eliminate the microflora of the gut. This can occur, for example, due to antibiotics, chemotherapy, or radiation. Furthermore, when the fiber intake of the patient is restricted, such as with some current elemental diets, there is no substrate for microorganism digestion even if the microflora are viable.


Because, in the above-identified conditions, short chain fatty acids cannot be used by the gastrointestinal tract as an energy substrate, gastrointestinal integrity and function cannot be maintained.

WO 90/12080 discloses structured triglycerides which have at least one short chain fatty acid on a glycerol backbone and at least one medium or long chain fatty acid on the glycerol backbone. The structured triglycerides may be used as parenteral nutrition and dietary supplements.

This invention provides the use of a lipid containing short chain fatty acids selected from fatty acids having 2 to 5 carbon atoms for the preparation of a medicament for maintaining gastrointestinal integrity and function in patients, the lipid upon hydrolysis yielding only short chain fatty acids. The medicament maintains gastrointestinal integrity and function in conditions where normal short chain fatty acid (SCFA) substrates, provided by bacterial fermentation of carbohydrates, are inadequate due to the clinical condition of the patient. By providing the short chain fatty acid in a lipid form of free fatty acid, triglyceride, phospholipid, or cholesterol ester one is able to avoid the clinical defect and allow the gastrointestinal tract to continue to maintain its integrity and function. This is essential to good nutritional status, disease resistance, immune competence, and rapid recovery from the disease state.

The lipids containing the short chain fatty acids of this invention can be provided either in enteral preparations administered by mouth, nasogastric, gastric or jejunostomy tube. Additionally, the lipids containing the short chain fatty acids of this invention can also be administered as a parenteral preparation by peripheral or central venous infusions. Additionally, the lipids containing the short chain fatty acids can be administered directly into the colon by enema. The medicament may be in the form of an emulsion.

The short chain fatty acids can be provided by hydrolysis of a triglyceride, diglyceride, or monoglyceride. For example, the short chain fatty acids can be provided by hydrolysis of a structure such as:



wherein R-COO-, R'-COO- and R''-COO- represent either the same or different short chain fatty acid residues.

The short chain fatty acid can contain from two to five carbon atoms, for example, acetic, propionic, butyric, valeric and isovaleric acid.

In an embodiment, the short chain fatty acids are provided in compositions including a fat content having a range of from approximately 12% to about 45% of the total caloric content (19 grams to 53 grams per 500 ml) of the composition. In an embodiment of the present invention, the short chain fatty acids comprise approximately 10% to about 50% of the total caloric percent of the fat content of the composition (1.9 grams to 26.5 grams per 500 ml). Hence the short chain fatty acids may supply 1.2% to 22.5% of the total caloric content of the composition. The remainder of the lipids can be made up of medium chain triglycerides and long chain triglycerides.

Additional features and advantages of the present invention are described in, and will be apparent from, the detailed description of the presently preferred embodiments.

EP 0 451 750 B1

The short chain fatty acids can be administered with a nutritional source including carbohydrates, vitamins, minerals, pectins, amino acids and lipids.

The short chains fatty acids of the present invention can be administered either parenterally or enterally. As an enteral preparation, the short chain fatty acid composition can be administered by mouth, nasogastric, gastric, or jejunostomy tube. As a parenteral preparation, the short chain fatty acids of the present invention can be administered by peripheral or central venous infusions. The short chain fatty acids can also be administered directly into the colon by enema.

By way of example, formulations of the present invention including short chain fatty acids will now be given.

10 Example 1

A medicament in the form of an enteral formulation for tube feeding or oral feeding can have the composition set forth below. The formulation provides a complete liquid nutrition formula suitable for various clinical indications. The composition provides complete and balanced nutrients and therefore can be used as a supplement or a total feeding. The formulation is isotonic and has a low renal solute load, making it an ideal standard tube-feeding formula.

NUTRIENT COMPOSITION	per 250 ml AMOUNT
CALORIES kcal	250
PROTEIN g (% of calories)	10 (16%)
CARBOHYDRATE g (% of calories)	31.8 (51%)
FAT g (% of calories)	9.5 (33%)
SCFA g	1.9
MCT g	3.6
LCT g	4.0
VITAMINS	
VITAMIN A IU	940
VITAMIN D IU	50
VITAMIN E IU	5
VITAMIN K μ g	31
VITAMIN C mg	25
THIAMINE (B ₁) mg	0.38
RIBOFLAVIN (B ₂) mg	0.43
NIACIN mg	5
VITAMIN B ₆ mg	0.75
FOLIC ACID μ g	100
PANTOTHENIC ACID mg	2.5
VITAMIN B ₁₂ μ g	1.5
BIOTIN μ g	75
CHOLINE mg	110
MINERALS	
SODIUM mg	125
POTASSIUM mg	313
CHLORIDE mg	250
CALCIUM mg	125

EP 0 451 750 B1

(continued)

NUTRIENT COMPOSITION	per 250 ml AMOUNT
PHOSPHORUS mg	125
MAGNESIUM mg	62.5
IRON mg	2.3
IODINE μ g	19
COPPER mg	0.25
ZINC mg	2.5
MANGANESE mg	0.5

Example 2

A medicament formulated for tube feeding or oral feeding, pursuant to the present invention, can have the formulation set forth below. The formulation provides a nutritionally complete and high caloric liquid nutrition composition, indicated when increased calories are needed in a concentrated form. Low osmolality allows the formulation to be used as a tube feeding.

EP 0 451 750 B1

NUTRIENT COMPOSITION	per 250 ml AMOUNT
CALORIES kcal	375
PROTEIN g (% of calories)	15 (16%)
CARBOHYDRATE g (% of calories)	42.5 (45%)
FAT g (% of calories)	16.9 (39%)
SCFA g	5.0
MCT g	5.9
LCT g	6.0
VITAMINS	
VITAMIN A IU	1400
VITAMIN D IU	75
VITAMIN E IU	7.5
VITAMIN K µg	47
VITAMIN C mg	38
THIAMINE (B ₁) mg	0.56
RIBOFLAVIN (B ₂) mg	0.64
NIACIN mg	7.5
VITAMIN B ₆ mg	1.1
FOLIC ACID µg	150
PANTOTHENIC ACID mg	3.8
VITAMIN B ₁₂ mcg	2.3
BIOTIN µg	110
CHOLINE mg	170
MINERALS	
SODIUM mg	188
POTASSIUM mg	470
CHLORIDE mg	375
CALCIUM mg	188
PHOSPHORUS mg	188
MAGNESIUM mg	94
IRON mg	3.4
IODINE µg	28
COPPER mg	0.38
ZINC mg	3.8
MANGANESE mg	0.75

EP 0 451 750 B1

Example 3

A medicament, an enteral formulation for tube feeding or oral feeding, pursuant to the present invention, can have the formulation set forth below. The formulation provides a complete and balanced enteral formula that can be used as a tube or oral feeding and is indicated for severe fluid restriction or extremely high caloric requirements.

NUTRIENT COMPOSITION	per 250 ml AMOUNT
CALORIES kcal	500
PROTEIN g (% of calories)	20 (16%)
CARBOHYDRATE g (% of calories)	49 (39%)
FAT g (% of calories)	26.5 (45%)
SCFA g	13.0
MCT g	6.0
LCT g	7.5
VITAMINS	
VITAMIN A IU	1900
VITAMIN D IU	100
VITAMIN E IU	10
VITAMIN K µg	63
VITAMIN C mg	50
THIAMINE (B ₁) mg	0.75
RIBOFLAVIN (B ₂) mg	0.85
NIACIN mg	10
VITAMIN B ₆ mg	1.5
FOLIC ACID mcg	200
PANTOTHENIC ACID mg	5
VITAMIN B ₁₂ µg	3
BIOTIN µg	150
CHOLINE mg	230
MINERALS	
SODIUM mg	250
POTASSIUM mg	625
CHLORIDE mg	500
CALCIUM mg	250
PHOSPHORUS mg	250
MAGNESIUM mg	125
IRON mg	4.5
IODINE µg	38
COPPER mg	0.5
ZINC mg	5
MANGANESE mg	1

EP 0 451 750 B1

Example 4

A liquid, isotonic, medicament including short chain fatty acids, pursuant to the present invention, can have the following composition. The composition provides an easily digested formula.

5

10

15

20

25

30

35

40

45


50

55

NUTRIENT COMPOSITION	per 250 ml AMOUNT
CALORIES kcal	500
PROTEIN g	20.0
CARBOHYDRATE g	63.5
FAT*** g	19.5
SCFA g	6.5
MCT g	7.0
LCT g	6.0
VITAMINS	
VITAMIN A IU	1875
VITAMIN D IU	100
VITAMIN E IU	10
VITAMIN K µg	62.5
VITAMIN C mg	50
THIAMINE (B ₁) mg	0.75
RIBOFLAVIN (B ₂) mg	0.85
NIACIN mg	10
VITAMIN B ₆ mg	1.5
FOLIC ACID µg	200
PANTOTHENIC ACID mg	5
VITAMIN B ₁₂ µg	3
BIOTIN µg	150
CHOLINE mg	225
MINERALS	
SODIUM mg	250
POTASSIUM mg	625
CHLORIDE mg	500
CALCIUM mg	300
PHOSPHORUS mg	250
MAGNESIUM mg	150
IRON mg	4.5
IODINE µg	37.5
COPPER mg	0.5
ZINC mg	5.0
MANGANESE mg	1.0

Claims

1. Use of a lipid containing short chain fatty acids selected from fatty acids having 2 to 5 carbon atoms for the preparation of a medicament for maintaining gastrointestinal integrity and function in patients, the lipid upon hydrolysis yielding only short chain fatty acids.
2. Use according to claim 1 wherein the lipid comprises at least one mono-, di- or triglyceride which yields only short chain fatty acids on hydrolysis.
3. Use according to claim 1 in which the lipid has the formula




in which R-COO-, R'-COO- and R''-COO- each represent the same or different short chain fatty acid residue having 2 to 5 carbon atoms.

4. Use according to any preceding claim in which the short chain fatty acid is at least one of acetic, propionic, butyric, valeric or isovaleric acid.
5. Use according to any preceding claim in which the medicament is adapted for enteral or parenteral administration.
6. Use according to any preceding claim wherein the short chain fatty acids supply 1.2 to 22.5% of the total caloric content of the medicament.
7. Use according to any preceding claim wherein the medicament is in the form of an emulsion.
8. Use according to any preceding claim wherein the lipids containing the short chain fatty acids form part of a lipid source which provides 12 to 45% of the caloric content of the medicament.

Patentansprüche

1. Verwendung eines Lipids, das kurzkettige Fettsäuren enthält, die aus Fettsäuren mit von 2 bis 5 Kohlenstoffatomen ausgewählt sind, zur Herstellung eines Medikaments zur Aufrechterhaltung der gastrointestinalen Integrität und Funktion bei Patienten, wobei das Lipid bei seiner Hydrolyse nur kurzkettige Fettsäuren liefert.
2. Verwendung nach Anspruch 1, bei der das Lipid wenigstens ein Mono-, Di- oder Triglycerid aufweist, das bei der Hydrolyse nur kurzkettige Fettsäuren liefert.
3. Verwendung nach Anspruch 1, bei der das Lipid die Formel aufweist



worin R-COO-, R'-COO- und R''-COO- jeweils den gleichen oder einen unterschiedlichen kurzen Fettsäurerest mit von 2 bis 5 Kohlenstoffatomen bedeutet.


4. Verwendung nach irgend einem vorausgehenden Anspruch, bei der die kurzkettige Fettsäure wenigstens eine von Essigsäure, Propionsäure, Buttersäure, Valeriansäure oder Isovaleriansäure ist.

EP 0 451 750 B1

5. Verwendung nach irgend einem vorausgehenden Anspruch, bei der das Medikament für eine enterale oder parenterale Verabreichung bestimmt ist.
6. Verwendung nach irgend einem vorausgehenden Anspruch, bei der die kurzkettigen Fettsäuren von 1,2 bis 22% des gesamten Brennwertgehalts des Medikaments liefern.
7. Verwendung nach irgend einem vorausgehenden Anspruch, bei der das Medikament in Form einer Emulsion vorliegt.
8. Verwendung nach irgend einem vorausgehenden Anspruch, bei der die Lipide, die die kurzkettigen Fettsäuren enthalten, Teil einer Lipidquelle bilden, die 12 bis 45% des Brennwertgehalts des Medikaments liefert.

Revendications

1. Utilisation d'un lipide contenant des acides gras à chaîne courte choisis parmi des acides gras ayant 2 à 5 atomes de carbone pour la préparation d'un médicament destiné au maintien de l'intégrité et du fonctionnement du tractus gastro-intestinal chez des patients, le lipide, par hydrolyse, donnant seulement des acides gras à chaîne courte.
2. Utilisation suivant la revendication 1, dans laquelle le lipide comprend au moins un mono-, di- ou triglycéride qui donne seulement, par hydrolyse, des acides gras à chaîne courte.
3. Utilisation suivant la revendication 1, dans laquelle le lipide répond à la formule



dans laquelle R-COO-, R'-COO- et R''-COO- représentent chacun des résidus d'acides gras à chaîne courte identiques ou différents ayant 2 à 5 atomes de carbone.

4. Utilisation suivant l'une quelconque des revendications précédentes, dans laquelle l'acide gras à chaîne courte consiste en au moins un des acides acétique, propionique, butyrique, valérique et isovalérique.
5. Utilisation suivant l'une quelconque des revendications précédentes, dans laquelle le médicament est apte à l'administration entérale ou parentérale.
6. Utilisation suivant l'une quelconque des revendications précédentes, dans laquelle les acides gras à chaîne courte fournissent 1,2 à 22,5 % de la teneur totale en calories du médicament.
7. Utilisation suivant l'une quelconque des revendications précédentes, dans laquelle le médicament est sous forme d'une émulsion.
8. Utilisation suivant l'une quelconque des revendications précédentes, dans laquelle les lipides contenant les acides gras à chaîne courte font partie d'une source de lipides qui fournit 12 à 45 % de la teneur en calories du médicament.